Bone loss in patients with inflammatory bowel disease is less than expected: A follow-up study

Scandinavian Journal of Gastroenterology

Volumn 34, Issue 7, 1999, Pages 696-702

  Schulte, C ^a   Dignass, A U ^a   Mann, K ^a   Goebell, H ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Bone loss; Bone metabolism; Bone mineral density; Inflammatory bowel disease; Osteoporosis

Indexed keywords

CALCIUM; COLESTYRAMINE; CORTICOSTEROID; ESTROGEN; ORAL CONTRACEPTIVE AGENT; VITAMIN D;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; CORTICOSTEROID THERAPY; CROHN DISEASE; ENTERITIS; FEMALE; HUMAN; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; ULCERATIVE COLITIS;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BODY COMPOSITION; BONE DENSITY; BONE RESORPTION; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS;

EID: 0032775747     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655299750025903     Document Type: Article

References (33)

1. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with bowel disease. Gut 1997;40:228-33.
2. Silvennoinen JA, Karttunen TJ, Niemelä SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995;37:71-6.
3. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994;107:1031-9.
4. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: A population based study. Gut 1997;40:313-9.
5. Nuti R, Martini G, Gennari C. Age-related changes of whole skeleton and body composition in healthy men. Calcif Tissue Int 1995;57:336-9.
6. Scharla SH, Minne HW, Lempert UG, Leidig G, Hauber M, Raedsch R, et al. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis). Exp Clin Endocrinol Diab 1994;102:44-9.
7. Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflammatory Bowel Dis 1998;4:268-75.
8. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995;108:417-22.
9. Bischoff SC, Herrmann A, Göke M, Manns MP, von zur Mühlen A, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997;92:1157-63.
10. Motley RJ, Crawley EO, Evans C, Rhodes J, Compston JE. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel desease. Gut 1988;29:1332-6.
11. Clements D, Motley RD, Evans WD, Harries AD, Rhodes J, Coles RJ, et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992;27:1055-60.
12. Motley RJ, Clements D, Evans WD, Crawley EO, Evans C, Rhodes J, et al. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner 1993;23:95-104.
13. Staun M, Tjellesen L, Thale M, Schaadt O, Jarnum S. Bone mineral content in patients with Crohn's disease. Scand J Gastroenterol 1997;32:226-32.
14. Roux C, Abitbol V, Chaussade S, Kolta S, Guillemant S, Dougados M, et al. Bone loss in patients with inflammatory bowel disease: A propective study. Osteoporosis Int 1995;5:156-60.
15. Garnero P, Hausherr E, Chapuy MC. Markers of bone marrow resorption predict hip fracture in elderly women: The Epidos prospective study. J Bone Min Res 1996;11:1531-8.
16. Chesnut CHI, Bell NH, Clark GF, Drinkwater BL, English SC, Johnston CC, et al. Hormone replacement therapy in post-menopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37.
17. Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Monaco R, Gennari C. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Min Res 1997;12:624-31.
18. Rachmilewitz D, DeSonto SM. Coated mesalazine (5-aminosalicylic acid) versus Sulphalazine in the treatment of active ulcerative colitis: A randomised trial. Br Med J 1989;298:82-6.
19. Singleton JW, Kern F, Best WR, Becktel JM. Development of a Crohn's disease activity index. Gastroenterology 1976;70:439-44.
20. Hanson DA, Weis MAE, Bollen A-M, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Min Res 1992;7:1251-8.
21. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-52.
22. Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Min Res 1996;11: 337-48.
23. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338:736-46.
24. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993;34:1543-6.
25. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235-42.
26. Neef B, Maier K-E, von Gaisberg U. Schwere osteoporose bei einer jungen patientin mit morbus Crohn. Dtsch Med Wochenschr 1991;116:1055-60.
27. McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann Intern Med 1998;128: 253-61.
28. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Min Res 1995;10:641-9.
29. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 1994;78:955-9.
30. Marshall LA, Cain DF, Dmowski WP, Chesnut CH. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy. Obstet Gynecol 1996;87:350-4.
31. Ravn P, Christiansen JO, Baumann M, Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment. Bone 1998;22:559-64.
32. Silvennoinen J, Risteli L, Karttunen T, Risteli J. Increased degradation of type I collagen in patients with inflammatory bowel disease. Gut 1996;38:223-8.
33. Compston JE. Review article: Osteoporosis, corticosteroids and inflammatory bowel disease. Aliment Pharmacol Ther 1995;9: 237-50.